Information  X 
Enter a valid email address

Antisoma plc (SRC)

  Print      Mail a friend       Annual reports

Thursday 12 February, 2009

Antisoma plc

ASA404 to be developed in breast cancer

London, UK, and Cambridge, MA, 12 February 2009 - Antisoma plc
(LSE:ASM; USOTC:ATSMY) announces that its Tumour-Vascular Disrupting
Agent, ASA404, will be evaluated by Novartis as a treatment for
HER2-negative metastatic breast cancer. This indication is being
prioritised ahead of prostate cancer, in which a phase II trial has
been completed. Details of the plans for trials in breast cancer will
be available later this year.

Antisoma and Novartis have a worldwide development and
commercialisation agreement for ASA404. Trials in breast cancer will
be in addition to two ongoing pivotal phase III trials in patients
with non-small cell lung cancer, one (ATTRACT-1) testing ASA404 as a
first-line treatment and the other (ATTRACT-2) evaluating ASA404 as a
second-line treatment. Because ASA404 acts by disrupting tumour blood
vessels, it has potential application against a variety of solid
tumours, all of which depend on tumour blood vessels to survive and

Glyn Edwards, Antisoma's CEO, said: "We are very pleased that
Novartis is extending the development of ASA404 to metastatic breast
cancer.  This represents a significant additional opportunity for
ASA404. While there have been many advances in the treatment of
breast cancer, there remains a great need for new and innovative
approaches, especially for patients with metastatic cancer."

About metastatic breast cancer
Worldwide, more than a million women are diagnosed with breast cancer
and over 400,000 die from the disease each year. Metastatic breast
cancer is the most advanced stage (stage IV). Over 100,000 patients
present with stage IV disease each year in the US, Europe and Japan.

About ASA404
ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent
(Tumour-VDA) which selectively targets the blood vessels that nourish
tumours. The drug was discovered by Professors Bruce Baguley and
William Denny and their teams at the Auckland Cancer Society Research
Centre, University of Auckland, New Zealand. It was in-licensed by
Antisoma from Cancer Research Ventures Limited (now Cancer Research
Technology), the development and commercialisation company of the
Cancer Research Campaign (now Cancer Research UK), in August 2001. In
a randomised phase II study in non-small cell lung cancer, addition
of ASA404 to standard first-line chemotherapy was associated with a 5
month improvement in median survival. Worldwide rights to the drug
were licensed to Novartis AG in April 2007.

About Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company
that develops novel products for the treatment of cancer. The Company
has operations in the UK and the US. Please visit
for further information about Antisoma.


Glyn Edwards, CEO
Daniel Elger, VP, Marketing & Communications      +44 (0)7909 915 068
Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Skye             +44 (0)20 7466 5000
Buchanan Communications

Brian Korb                                        +1 646 378 2923
The Trout Group

Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.